Singapore Clinical Trial: Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): National Cancer Centre

Trial Status: NA

Principal Investigator(s): Aaron C. Tan

Published by HT Digital Content Services with permission from Health Daily Digest....